YD Bio Ltd

YD Bio Limited reported unaudited financial results for the six months ended June 30, 2026, showing revenue of $0.85 million, a 325.0% increase year-over-year. The company achieved net income of $6.7 million, compared to a net loss of $1.9 million in the same period last year. As of June 30, 2026, cash stood at $2,662,004, down from $6,007,615 at the end of 2025.

YD Bio announced that its affiliate EG BioMed US has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington. The Rhode Island license covers the clinical genetics specialty, while the Pennsylvania permit covers clinical chemistry and hematology. With these additions, the laboratory’s authorized multi-state operating footprint now extends to 46 U.S. states, plus Washington, D.C. and Guam. The expansion broadens patient access and supports the company’s DNA methylation–based early cancer detection operations, which include blood-based testing services for pancreatic, colorectal, breast, liver, and other gastrointestinal cancers.